Provider Tools

BV and STI co-infection, iron deficiency anemia trends, ACOG HIV and PrEP guidance, estetrol/drospirenone safety data

Gender-affirming hormone therapy builds on skills clinicians already have. Here's a practical starting point.

A 21-year-old patient (she/her) presents to your health center after a positive home urine pregnancy test last week. Based on a sure last menstrual period (LMP), the patient currently has an estimated gestational duration of 6 weeks. When you ask how she's feeling about being pregnant, she pauses and says, "Honestly? I don't know. I think I could see myself going either way. I just don't know what the right thing to do is." She has a 3-year-old at home, a job she's not sure allows for more time off, and a partner she describes as "supportive but not pushing me either way." She denies urgent safety concerns and has no significant medical history.

Your patient says they've "been doing research." What if that research came from an organized disinformation network? A guide to four sources SRH providers should recognize.

A 29-year-old G2P1 (she/they) presents for medication abortion at 8 weeks of gestation, consistent with a 6-week ultrasound demonstrating a single intrauterine pregnancy. She reports, “I think I got a shot after I had my son. Do I need a shot before I take the pills?" She reports her previous pregnancy was uncomplicated. She is not certain of her prior Rh status. She is not certain about a desire for future pregnancies.

From azole-resistant candida to the new ACOG guidance on BV partner therapy, recurrent vaginitis management has gotten more nuanced.

What providers need to know about correcting abortion misinformation and supporting patient autonomy